Carmen Hurtado de Mendoza Infantes

Leading global disease strategy, launch planning and commercial execution for rare disease therapies across international markets, partnering with regional and affiliate teams to accelerate global adoption and patient access. Responsible for global disease strategy, launch planning and commercial alignment across key markets including the US, Europe and Japan.

Led commercial strategy and market access across Spain and Portugal for the rare disease portfolio, driving launch readiness, market expansion and cross-functional alignment across medical, market access and policy teams.

Led commercial strategy and market development across Spain and Portugal for the acute care portfolio, supporting product launches and market access initiatives across key hospital accounts

Strategic advisor to global healthcare and investment organizations on oncology and hematology market dynamics, product strategy and commercialization pathways. Member of the expert advisory panel supporting market insights and strategic decision-making (consultancy basis).

Strategic advisor to global clients on CNS market dynamics, access landscape and commercial strategy, providing expert insights on therapeutic positioning and market development (consultancy basis).

Led the oncology business unit with full P&L responsibility, reporting to the General Manager and VP Global Oncology. Member of the leadership steering committee, responsible for portfolio strategy across colorectal cancer, pancreatic cancer, glioblastoma, leukemia and lymphoma. Led cross-company product transfer (Servier to Shire) ensuring global compliance, operational continuity and portfolio transition across markets. Developed and implemented a new go-to-market model and “People & Culture” transformation program in partnership with McKinsey.

Led the Oncology and CNS business units with full P&L responsibility, overseeing portfolio strategy, product launches and market access initiatives across Spain. Managed cross-company product transfer (Teva to Lundbeck) ensuring portfolio continuity and operational alignment across organizations. Expanded the specialty portfolio across oncology, multiple sclerosis and Parkinson’s disease, driving commercial growth and market development.

Led marketing strategy for the Oncology and CNS portfolio, driving product positioning, launch planning and market development across Spain. Partnered with medical and market access teams to strengthen portfolio competitiveness and expand presence in key hospital accounts.

Member of the start-up leadership team in Spain responsible for building the oncology and specialty portfolio strategy. Led the launch of a new osteosarcoma therapy and developed strategic marketing plans across oncology, diabetes and HTA. Drove cross-functional collaboration with medical and market access teams to support portfolio growth.

Led the launch of a new diabetes therapy and managed key national accounts across Spain. Oversaw coordination with a 300-person sales organization to support product adoption and commercial performance.

Managed strategic hospital accounts across Spain, supporting the growth of the diabetes portfolio and strengthening relationships with key stakeholders.

Consistently delivered strong commercial performance and was recognized with the APEX Award for Top 5 Sales Representatives.

Managed public sector accounts, developing early experience in complex institutional sales.

Developed foundational sales experience managing public administration accounts and building long-term customer relationships.